Abstract: This invention encompasses anthranilamides with heteroarylsulfonyl side chain, process for their preparation, their use as medicament or diagnostic aid, and pharmaceutical preparations containing them. Compounds of formula I, in which R1 to R7 have the meanings stated in the claims, act on the Kv1.5 potassium channel and inhibit a potassium current which is referred to as the ultra-rapidly activating delayed rectifier in the atrium of the human heart. They are therefore suitable as novel antiarrhythmic ingredients, such as for the treatment and prophylaxis of atrial arrhythmias, e.g. atrial fibrillation (AF) or atrial flutter.
Type:
Grant
Filed:
June 12, 2002
Date of Patent:
June 7, 2005
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Joachim Brendel, Thomas Böhme, Stefan Peukert, Heinz-Werner Kleemann
Abstract: A substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-one, compound of formula 1, wherein R1, R2, R3, R4 and R5 are as defined herein, pharmaceutical composition comprising the compound and use of the compound for inhibiting pancreatic lipase, or the prophylaxis or treatment of obesity are described.
Type:
Grant
Filed:
February 27, 2003
Date of Patent:
May 31, 2005
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Karl Schoenafinger, Stefan Petry, Günter Müller, Armin Bauer, Hubert Otto Heuer
Abstract: Fluorinated cycloalkyl-derivatized benzoylguanidines of formula I are suitable as antiarrhythmic medicaments with a cardioprotective component for infarction prophylaxis and infarction treatment and for the treatment of angina pectoris. They also preventively inhibit the pathophysiological processes associated with the development of ischemia-induced damage, in particular in the triggering of ischemia-induced cardiac arrhythmias and of heart failure.